Therefore,
Survival patients multiplied 2 20:
The survival of patients with pulmonary adenocarcinoma. However, a malignant tumor representing the main histology of lung cancer non -small cells (CPNPC), has significantly improved in the past 20 years, observes the college of pneumologists of general hospitals in France in an epidemiological study published in the International Medicine Journal (see box). However, “” In 2020, the SG rate [survie globale, ndlr] At 3 years for all patients with pulmonary adenocarcinoma was 38.6 %, compared to 16.3 % in 2000 and 21.2 % in 2010. Meanwhile, The overall median of survival rose from 8.5 months in 2000 to 20.7 months in 2020 “, This indicates its authors.
The survival rate however depends strongly depending on the stage of the disease at the time of diagnosis. In addition, In 2020, it was 84.0 % to three years for stages I, 65.9 % for stages II, survival patients multiplied 2 20 49.5 % for stadiums III and only 21.3 % for stages IV. Meanwhile, In metastatic patients, global survival at 3 years was 36.0 % for those with molecular alteration (EGFR, ALK, ROS1) treated by targeted therapy, against 18.5 % in the absence of alteration. However, For the latter, it was 36.2 % at 3 years with immunotherapy on the front line, compared to 14.3 % without immunotherapy. “” The median survival went from 4.2 to 21.0 months with immunotherapy “, Details the study. Women, younger patients, non-smoking patients and those diagnosed at an earlier stage have better survival rates.
Cancer that remains bad prognosis despite therapeutic innovations – Survival patients multiplied 2 20
To explain this improvement. the authors of course advance the progress made on therapies, including targeted therapy and immunotherapy. However. lung cancer, ” First cause of cancer mortality worldwide, there remains a major public health issue because of its high incidence and its survival patients multiplied 2 20 unfavorable prognosis. By drawing up the assessment of its 20 years of existence. the National Institute for the Fight against Cancer noted, a drop in the incidence of lung cancer in men, but deplored its increase in women (+5%). He called to continue research but also to strengthen prevention by the fight against risk factors, including tobacco. Despite the innovations observed in the field of treatments. ” The prognosis remains very linked to the stadium at the time of diagnosis Recalls the study on its side. “” This progress highlights the importance of early detection. the molecular characterization of tumors and fair access to innovative treatments for all patients. »
Study methodology
Since 2000, the college of pulmonologists from general hospitals in France, has conducted epidemiological studies (KBP) every ten years. These make it possible to “follow the evolution of demography. to analyze the results, particularly in terms of survival patients multiplied 2 20 global survival. To carry out this study. a collective has collected all new cases of primitive lung cancer observed in general hospitals, or:
- 5,667 patients in 2000
- 7,051 patients in 2010
- And 8,999 patients, including 50,15 cases of adenocarcinoma in 2020
- The average age at diagnosis in 2020 was 67.2%
- 40% of these patients were women, compared to 24.5% in 2000.
« The proportion of patients aged 80 or over doubled in 20 years, from 6.4 % to 12.7 % “, Specifies the study.
Access the publication
Further reading: Hope in Alzheimer’s disease – postnatal maintenance really helps to detect it earlier – Disturbing ADHD deviations in Quebec: “We jump on the diagnosis and the pill more easily” – Thursday July 31, 2025-Lourdes-actu – Weight loss facilitates cell renewal.
